Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD

2.99  -0.15 (-4.78%)

After market: 3.18 +0.19 (+6.35%)

Fundamental Rating

2

Taking everything into account, EKSO scores 2 out of 10 in our fundamental rating. EKSO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. EKSO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, EKSO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EKSO had negative earnings in the past year.
In the past year EKSO has reported a negative cash flow from operations.
EKSO had negative earnings in each of the past 5 years.
In the past 5 years EKSO always reported negative operating cash flow.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -39.52%, EKSO is not doing good in the industry: 64.17% of the companies in the same industry are doing better.
EKSO has a worse Return On Equity (-85.03%) than 60.43% of its industry peers.
Industry RankSector Rank
ROA -39.52%
ROE -85.03%
ROIC N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

With a Gross Margin value of 53.39%, EKSO perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
EKSO's Gross Margin has improved in the last couple of years.
EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EKSO has more shares outstanding
The number of shares outstanding for EKSO has been increased compared to 5 years ago.
Compared to 1 year ago, EKSO has an improved debt to assets ratio.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -12.80, we must say that EKSO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.80, EKSO is not doing good in the industry: 82.35% of the companies in the same industry are doing better.
EKSO has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
EKSO has a Debt to Equity ratio (0.28) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z -12.8
ROIC/WACCN/A
WACC6.26%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.35 indicates that EKSO has no problem at all paying its short term obligations.
EKSO has a Current ratio (2.35) which is in line with its industry peers.
EKSO has a Quick Ratio of 1.77. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.77, EKSO is in line with its industry, outperforming 47.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.77
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.97%, which is quite impressive.
Looking at the last year, EKSO shows a decrease in Revenue. The Revenue has decreased by -1.94% in the last year.
EKSO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.19% yearly.
EPS 1Y (TTM)43.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.41%
Revenue 1Y (TTM)-1.94%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%-58.44%

3.2 Future

EKSO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.90% yearly.
EKSO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.01% yearly.
EPS Next Y35.58%
EPS Next 2Y25.68%
EPS Next 3Y20.9%
EPS Next 5YN/A
Revenue Next Year-1.46%
Revenue Next 2Y18.41%
Revenue Next 3Y18.01%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M 25M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EKSO. In the last year negative earnings were reported.
Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as EKSO's earnings are expected to grow with 20.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3Y20.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EKSO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (8/8/2025, 8:00:02 PM)

After market: 3.18 +0.19 (+6.35%)

2.99

-0.15 (-4.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners9.63%
Inst Owner Change-22.06%
Ins Owners5.93%
Ins Owner Change5.66%
Market Cap7.80M
Analysts82.5
Price Target35.45 (1085.62%)
Short Float %4.11%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.26%
Min EPS beat(2)-71.57%
Max EPS beat(2)-6.95%
EPS beat(4)2
Avg EPS beat(4)-17.48%
Min EPS beat(4)-71.57%
Max EPS beat(4)6.63%
EPS beat(8)3
Avg EPS beat(8)-21.63%
EPS beat(12)4
Avg EPS beat(12)-17.76%
EPS beat(16)8
Avg EPS beat(16)-7.67%
Revenue beat(2)0
Avg Revenue beat(2)-14.85%
Min Revenue beat(2)-28.45%
Max Revenue beat(2)-1.24%
Revenue beat(4)0
Avg Revenue beat(4)-15.73%
Min Revenue beat(4)-28.45%
Max Revenue beat(4)-1.24%
Revenue beat(8)2
Avg Revenue beat(8)-10.4%
Revenue beat(12)3
Avg Revenue beat(12)-5.17%
Revenue beat(16)6
Avg Revenue beat(16)-1.33%
PT rev (1m)-7.33%
PT rev (3m)595%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1587.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-1587.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.44
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-6.64
EYN/A
EPS(NY)-3.6
Fwd EYN/A
FCF(TTM)-3.21
FCFYN/A
OCF(TTM)-3.2
OCFYN/A
SpS6.72
BVpS4.86
TBVpS3.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.52%
ROE -85.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.39%
FCFM N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.47%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 1.77
Altman-Z -12.8
F-Score5
WACC6.26%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.41%
EPS Next Y35.58%
EPS Next 2Y25.68%
EPS Next 3Y20.9%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.94%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%-58.44%
Revenue Next Year-1.46%
Revenue Next 2Y18.41%
Revenue Next 3Y18.01%
Revenue Next 5YN/A
EBIT growth 1Y24.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.19%
OCF growth 3YN/A
OCF growth 5YN/A